Zoetis Inc. (ZTS)
| Market Cap | 52.79B |
| Revenue (ttm) | 9.40B |
| Net Income (ttm) | 2.65B |
| Shares Out | 440.69M |
| EPS (ttm) | 5.94 |
| PE Ratio | 20.18 |
| Forward PE | 18.09 |
| Dividend | $2.00 (1.67%) |
| Ex-Dividend Date | Oct 31, 2025 |
| Volume | 4,828,368 |
| Open | 120.43 |
| Previous Close | 120.24 |
| Day's Range | 118.52 - 121.31 |
| 52-Week Range | 117.26 - 181.85 |
| Beta | 0.96 |
| Analysts | Buy |
| Price Target | 185.00 (+54.44%) |
| Earnings Date | Nov 4, 2025 |
About ZTS
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]
Financial Performance
In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ZTS stock is "Buy." The 12-month stock price target is $185.0, which is an increase of 54.44% from the latest price.
News
Zoetis: Why I'm Still Holding The Stock But Advise Against New Positions
Zoetis faces ongoing headwinds as Librela sales disappoint, triggering a sharp post-earnings sell-off and continued stock weakness. Librela's decline, fueled by social media concerns about side effect...
Zoetis Remains A Strong Buy Following Market Overreaction To Q3 Earnings
Zoetis Inc. is trading at historically low valuations despite continued EPS and margin growth, following a sharp post-earnings selloff. ZTS's Q3 results showed resilient profitability, but weaker guid...
Zoetis Inc. (ZTS) Q3 2025 Earnings Call Transcript
Zoetis Inc. ( ZTS) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Steven Frank - Vice President of Investor Relations Kristin Peck - CEO & Director Wetteny Joseph - Executive...
Zoetis Stock Outlook Clouded By Rising Competitive Pressures
Animal health firm Zoetis Inc. (NYSE:ZTS) on Tuesday reported a third-quarter 2025 adjusted earnings per share of $1.70.
Zoetis: No Longer A Growth Stock
Zoetis shares have underperformed, falling over 25% in the past year, with recent guidance disappointing investors. Organic growth is slowing, especially in the United States, as core products reach m...
This Animal Health Stock Tanks on Earnings. Pig and Chicken Medication Revenue Slumps.
Zoetis slashes its full-year outlook.
Zoetis trims annual revenue forecast on muted demand for animal treatments, shares slide
Animal healthcare company Zoetis on Tuesday trimmed its annual revenue forecast on expectations of softer demand for its medicines and vaccines for pets and livestock, sending its shares down over 13%...
Zoetis Announces Third Quarter 2025 Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2025. The company reported revenue of $2.4 billion for th...
Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovatio...
Zoetis: High-Quality Compounder For Patient Long-Term Dividend Growth Investors
Zoetis is a US-based company involved in the discovery, development, manufacture, and marketing of animal medicines and vaccines. ZTS has increased its dividend for 13 consecutive years. This streak i...
Buy Zoetis Stock Today?
Zoetis (ZTS) stock warrants your attention. Why? Because it offers high margins – indicative of pricing power and the ability to generate cash – at a discounted price.
Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Portela becomes first mAb therapy with a three-month dosing interval approved for the alleviation of pain associated with OA in cats.
Zoetis Appoints Stephanie Tilenius to its Board of Directors
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms....
Zoetis Stock: Outlook Remains Muted
Zoetis Inc. (NYSE:ZTS) is currently in its final 18th phase of the Adhishthana cycle on the weekly charts. Having formed a poor triad structure, the stock's outlook doesn't look encouraging.
Zoetis Announces Health Canada Approval of Lenivia® (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in Dogs
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Lenivia approval by Health Canada marks major milestone in the company's continued innovation for canine OA pain.
Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Lenivia will be a new antibody therapy that reduces OA pain in dogs for three months with one injection.
Zoetis Declares Fourth Quarter 2025 Dividend
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will ...
Top 50 High-Quality Dividend Growth Stocks For October 2025
I track a universe of 50 high-quality dividend growth stocks to identify opportune investments based on valuation and future return potential. As of October 2, 2025, 22 stocks offer attractive future ...
Top 15 High-Growth Dividend Stocks For October 2025
The Top 15 High-Growth Dividend Stock list for October 2025 targets a 12% long-term return, despite underperforming SPY and VIG in September. These 15 stocks offer a 1.4% average yield and have grown ...
Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that Dectomax®-CA1 Injectable is the first and only parasite control product to receive conditional approval from ...
Pet Pain For Investor Gain
ZTS is fundamentally a companion animal company, with the segment driving 68% of 2024 revenue and projected to reach 71% by 2030, fueled by aging pet demographics in the US. OA pain franchise, Librela...
Zoetis to Host Webcast and Conference Call on Third Quarter 2025 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, November 4, 2025. Chief Executive Officer Kristin...
Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Zoetis' Portela will be the first long-acting anti-NGF mAb therapy for cats and is designed to provide 3 months of OA pain relief...
Zoetis Inc. (ZTS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Zoetis Inc. (NYSE:ZTS) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:05 PM EDT Company Participants Kristin Peck - CEO & Director Wetteny Joseph - Executive VP & CFO Con...
Top 50 High-Quality Dividend Stocks For September 2025
I track a universe of 50 high-quality dividend growth stocks to identify attractive investment opportunities based on valuation and future return potential. My custom valuation model highlights 23 sto...